BELGIUM – Bone therapeutics, a cell therapy company that focuses on orthopedic treatment, has signed a loan agreement worth €16m with European Investment Bank (EIB) to bolster its ongoing development and innovation of orthopedic treatment. The EIB loan financing will be disbursed in two tranches of €8 million each, subject to conditions precedent. It will used to support and prepare Bone Therapeutics’ lead asset, the enhanced visco supplement JTA-004 for future regulatory approval and commercialization. JTA-004, is being evaluated in a registrational phase III clinical trial for the treatment of…
Read MoreBone Therapeutics secures loan worth €16m from the European Investment Bank
